Diagnosis and surveillance of Barrett's esophagus (BE) and eosinophilic esophagitis (EoE) have become emerging public health issues. Cytosponge is a novel, minimally invasive esophageal cell collection device. We aimed to assess the data on safety and acceptability of this device.
See related editorial on page 610; see related article 638.
T wo chronic esophageal diseases-Barrett's esophagus (BE) and eosinophilic esophagitis (EoE)-have become emerging issues in the public health over the last several decades. [1] [2] [3] BE develops on the background of long-standing gastroesophageal reflux disease (GERD) and is defined as a metaplastic change in the esophageal lining, from a squamous-type epithelium to a specialized columnar epithelium. The estimated population prevalence of BE is 1%-2%. 4 BE is a major risk factor for esophageal adenocarcinoma: a cancer with rapidly increasing incidence in the Western world. 5 Patients with chronic GERD and other risk factors (male sex, !50 years of age, white race, family history of BE or esophageal adenocarcinoma) may be offered endoscopic screening for the presence of BE 6 ; however, most BE cases remain undiagnosed. Patients with the benefit of a BE diagnosis undergo endoscopic surveillance with the aim to identify neoplastic changes within BE segment at the earliest possible stage. [7] [8] [9] Such patients are candidates for endoscopic treatment with either endoscopic mucosal resection or radiofrequency ablation (RFA), 10, 11 with excellent survival results for intramucosal disease. 12 EoE, on the other hand, is a relatively newly defined immune-mediated disease characterized by predominant eosinophilic inflammation of the esophagus (a peak count of !15 eosinophils per high-power field of biopsy tissue). 3 EoE is seen predominantly in younger men; however, it affects all age groups and both sexes. 13, 14 It is one of the most common condition in adult patients leading to food bolus impaction. As with BE, most cases of EoE are undiagnosed, and its incidence rate is reaching up to 12.8 per 100,000/year in some regions of the United States. 15 The aim of diagnosis and treatment is to control the symptoms, resolve esophageal eosinophilia, and reduce complications.
Although the nature of these 2 entities is highly disparate, both require long-term, endoscopic monitoring and repeated collection of mucosal samples to optimize and monitor the treatment. To perform systematic screening and surveillance for these conditions would constitute a huge burden on health care systems. A survey study analyzing trends in endoscopic volume in the United States showed that there was a 54% increase in upper gastrointestinal endoscopy between 2000 and 2009, with an estimated number of 6.9 million procedures performed in 2009. 16 The rising incidence of BE and EoE may have contributed to these numbers. Patients with EoE alone have an estimated annual health-care cost of as much as $1.4 billion in the United States. 17 While diagnostic esophagogastroduodenoscopy (EGD) is considered to be a safe procedure, it is not devoid of complications. The overall mortality rates for EGD are ranging from none to 1 in 2000 in various studies. 18 Perforation, a potentially life-threatening complication, is reported to occur from 1:2500 to 1:11,000 procedures. 19, 20 Moreover, many of the EGDs in the United States and Europe are performed under sedation, exposing patients to additional risks. These include cardiopulmonary complications, which account for as much as 60% of endoscopy adverse events (AEs) and an incidence ranging between 1 in 170 and 1 in 10,000. 21 Therefore, new, less invasive methods of esophageal mucosal sampling are being investigated. Cytosponge is a novel, minimally invasive cell collection device that consists of a 30-mm polyurethane sponge, contained within a capsule attached to a string. When withdrawn, the device collects esophageal cells for analysis ( Figure 1A ). The procedure requires minimal training and can be safely administered by a nurse in a primary care setting. Cytosponge has already been successfully used in several studies to identify BE and EoE. [22] [23] [24] The cells retrieved from the sponge are spun down and embedded to produce a pseudo-biopsy suitable for routine laboratory analysis ( Figure 1B-D) . To aid the identification of BE, the histopathological analysis is coupled with a diagnostic biomarker, trefoil factor-3 ( Figure 1C ). Of note, the utility of the Cytosponge goes beyond the confines of BE and EoE diagnosis since a range of pathologies affecting the esophagus and proximal stomach, such as esophageal candidiasis, esophageal ulcers, Heliobacter pylori infection, intestinal metaplasia at the cardia, and viral esophagitis can also be diagnosed. 25 The aim of this study was to combine data from 5 large trials on Cytosponge performed in patients with chronic GERD, BE, and EoE in 3 different countries (United Kingdom, United States, and Australia) to assess the overall safety and acceptability of this test.
What You Need to Know
Background Cytosponge is a minimally invasive esophageal cell collection device that has been used in several studies to detect Barrett's esophagus and assess disease activity in eosinophilic esophagitis.
Findings
Esophageal sampling with this device was shown to be a safe procedure with good acceptability ratings and a very low risk of serious adverse events.
Implications for patient care
Cytosponge is a promising tool to be used in the primary care setting as a screening and surveillance test for esophageal disorders, such as Barrett's esophagus and eosinophilic esophagitis.
Methods

Study Design and Study Participants
This was a retrospective, patient-level technical review of prospectively collected data. Studies included in the analyses were the BEST1 (Barrett's ESophagus Trial 1) trial, 23 BEST2 trial, 24 BEST-Australia trial, the ongoing BEST2-RFA study (NCT02106910), and Cytosponge Eosinophilic EoE study (NCT02114606). 22 Principal investigators of each trial shared the original trial databases. All studies were conducted with the use of Cytosponge approved by the UK Medicines and Healthcare Products Regulatory Agency.
Briefly, the setting and patients' eligibility criteria of each study were as follows:
BEST1 trial: individuals with chronic GERD managed in primary care with long-term proton pump inhibitor (>3 months).
BEST2 trial: patients with previously diagnosed BE (cases) and patients with GERD without BE (control group) referred to the secondary care unit for endoscopy.
BEST-Australia trial: patients with chronic GERD symptoms referred for endoscopy in a secondary care unit. BEST2-RFA trial: patients with BE with low-or highgrade dysplasia, who received RFA or are under surveillance following ablative treatment.
EoE study: patients with EoE referred for the secondary care unit to undergo clinically indicated endoscopy.
Exclusion criteria were generally consistent between studies and included bleeding disorders, known cirrhosis AE varices, history of esophageal surgery, dysphagia, and esophageal stricture. An overview of study characteristics is presented in Table 1 .
Cytosponge Procedure
The Cytosponge was administered in a similar fashion in each trial by trained research nurses. After swallowing the device in sitting position, the capsule coating disintegrates within 5 minutes upon reaching the stomach, revealing a 3-cm-diameter spherical mesh that is withdrawn by pulling the string. Following its retrieval, the string is cut, the Cytosponge is then immersed in SurePath Preservative Fluid (TriPath Imaging, Burlington, NC) and kept at 4 C until transported to the laboratory for processing. Hematoxylin and eosin staining and immunohistochemistry for trefoil factor-3 is then performed on paraffin-embedded Cytosponge specimens by adhering to standard hematoxylin and eosin and trefoil factor-3 protocols on a BOND-MAX autostainer (Leica Biosystems, Newcastle upon Tyne, United Kingdom).
Outcome Measures
Acceptability of the Cytosponge and subsequent endoscopy (regardless of sedation) was recorded using a visual analog scale (VAS), wherein 10 indicated the best and 0 the worst experience. Patients in secondary care studies (BEST2 trial, BEST-Australia trial, EoE study, BEST2-RFA trial) underwent the Cytosponge and endoscopy on the same day, whereas patients from BEST1 trial (primary care) had their endoscopy scheduled within 3 weeks and the acceptability score for endoscopy was not recorded. Number of swallow attempts and failure in swallowing the Cytosponge were noted. Failure to swallow was stated when the device could not be swallowed despite 3 attempts. Patients in BEST2 trial and EoE study had repeated Cytosponge tests. All serious AEs (SAEs) were reported in accordance to the Good Clinical Practice guidelines. Minor events, such as sore throat, were not systematically recorded.
Cytosponge Abrasions Grading System
An abrasion grading system was introduced to categorize the severity of abrasions following the Cytosponge procedure. The presence and degree of abrasions were recorded during subsequent EGD. Abrasions provide useful information on the most distal passage of the device (important for diagnosing BE) as well as a comparator with biopsies for the bleeding risk. The grading system is presented in Figure 2 .
Statistical Analysis
Statistics for continuous variables are expressed as median and interquartile range (IQR). The MannWhitney test was used to compare continuous variables between groups. The association between failure in swallowing the Cytosponge and risk factors was analyzed using multivariable regression model. We report odds ratio and 95% confidence interval adjusted for patient sex, study setting, body mass index, and indication. All statistical tests were 2 sided. For all analyses, P value <.05 was considered statistically significant. All analyses LGD, low-grade dysplasia; RFA, radiofrequency ablation. Figure 2 . The abrasion grading system after Cytosponge.
were performed using R software version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient Demographics
In total, data on 2418 patients from 5 studies between May 2008 and August 2017 were analyzed. Eighty-four patients were unable to swallow the Cytosponge (3.5%) and 50 were withdrawn due to study eligibility (2.1%), leaving 2284 patients who successfully underwent the Cytosponge test. The study cohort comprised 518 BEST1 trial patients (21.4%), 1498 BEST2 trial patients (62.0%), 224 BEST-Australia trial patients (9.3%), 76 BEST2-RFA trial patients (3.1%), and 102 EoE study patients (4.2%).
There were 1329 patients with GERD (55.0%), 987 patients with previously diagnosed BE (40.8%; 911 from the BEST2 trial and 76 from the BEST2-RFA trial), and 102 patients with EoE (4.2%). The median age was 62 (IQR, 54-68) years and the male-to-female ratio was 1.7:1.0. The median body mass index was 28.2 (IQR, 25.1-31.5) kg/m 2 , indicating that most patients were overweight. The median waist-to-hip ratio for women was 0.86 (IQR, 0.81-0.91), and for men it was 0.96 (IQR, 0.92-0.99). Smoking status was recorded for 1971 patients. Of these, 809 were reported as lifetime nonsmokers (41.0%), 971 as former smokers (49.2%), and 191 as active smokers (9.7%). The majority of patients who underwent endoscopy had been diagnosed with hiatus hernia (53.7%). Combined demographic data are presented in Table 2 .
Cytosponge Acceptability
Overall, 2672 Cytosponge tests were performed, of which 2289 had acceptability score recorded (85.7%). The endoscopy acceptability score was recorded for 1406 procedures in 1221 patients. Of these, 1175 endoscopies included data on sedation (96.2%), indicating that 402 EGDs were performed without sedation (34.2%) and 773 with sedation (65.8%).
The overall acceptability for the Cytosponge was satisfactory, with a median score of 6.0 (IQR, 5.0-8.0). This was significantly higher when compared with endoscopy without sedation with median VAS score of 5.0 (IQR, 3.0-7.0; P < .001), but still comparatively lower than endoscopy with sedation (VAS 8.0; IQR, 5.0-9.0; P < .001) (see Figure 3) . EoE patients had the highest acceptability for the test ( 
Failure to Swallow the Cytosponge
Eighty-four patients failed to swallow the Cytosponge (3.5%). The proportion of patients who were unable to swallow the device was over 2 times higher within BE patients than in GERD patients (5.7% vs 2.1%) and slightly higher within men as compared with women (3.9% vs 2.7%). All EoE patients successfully swallowed the device. The majority of successful tests were achieved with the first swallow attempt (90.1%). Using a multivariable regression model, we found that patients examined in secondary care setting were over 5 times more likely to fail swallowing the device as compared with primary care setting (odds ratio, 5.13; 95% confidence interval, 1.48-17.79; P < .01). High body mass index and gender were not associated with rates of failure in swallowing. Patients with previously diagnosed chronic diseases (BE and EoE combined) had a similar risk of swallow failure, when compared with patients with GERD. Supplementary Table 1 presents the multivariable regression model results.
Cytosponge AEs
Overall, of the 2672 Cytosponge tests performed, there were 12 SAEs reported, of which only 2 could be directly attributed to the Cytosponge (<1:2000). These included 1 detachment of the sponge and 1 pharyngeal bleeding after Cytosponge withdrawal. The others were related to endoscopic therapy performed immediately after the Cytosponge test (see Supplementary Table 2) . As sore throat is a frequent event following endoscopy, we did not consider it an AE and the data was not collected systematically across all studies. No late AEs, such as strictures, have been reported.
Cytosponge detachment occurred in a 76-year-old man with BE in the BEST2-RFA trial at the University of North Carolina. The patient did not report any discomfort when the device was retained. Because the Cytosponge test was performed in the secondary care setting, it was retrieved endoscopically on the same day. The detached device was found in the pylorus and was successfully retrieved with a Roth net without further adverse consequences for the patient.
There was 1 case of mild pharyngeal bleeding in a patient from BEST2 trial. The patient was on warfarin for atrial fibrillation, that was stopped before the procedure (international normalized ratio was 1.2). The bleeding resolved spontaneously and there was no drop in hemoglobin levels. He was hospitalized as a precautionary measure and was discharged home the next day.
Cytosponge Abrasions
A Cytosponge abrasions grading system was devised in November 2011. It categorizes abrasions into 5 categories based on visual appearance of abrasions during endoscopy. This grading system was used in BEST2 trial, BEST2-RFA trial, and EoE study. Overall, 1075 Cytosponge procedures were followed by an endoscopy with abrasion score assessment. In most of the cases (85.5%, 919 of 1075) Cytosponge caused no or only mild abrasions (grade 0-2). There were only 24 cases (2.2%) of severe post-Cytosponge abrasions (grade 4), and no cases of grade 5 abrasions that required endoscopic or surgical intervention. Of note, Cytosponge abrasions, even at the highest grade of 4, appear less severe when compared with current standard of care (quadrantic biopsies obtained every 2 cm -Seattle protocol), 26 as pictured in Figure 2 .
Discussion
This technical review of 5 large prospective studies on the performance of the Cytosponge showed that it is a safe procedure with good acceptability ratings. The test can be safely performed by a nurse in both the primary and secondary care setting, with minimal risk of AE. The Cytosponge test was feasible when used for screening purposes (GERD patients with high-risk for BE), as well as for surveillance (EoE and BE after endoscopic treatment).
Safety is paramount for any procedure especially when being performed in the primary care setting. Our review showed that of 2672 Cytosponge procedures there were only 2 SAE that could be directly attributed to the device (<1:2000) and both resolved without any ill effects for the patient. The detachment is the most concerning risk factor to both clinicians and patients. 27 However, a retained sponge in the stomach would not be expected to cause any symptoms as was the case in the patient reported here. As objects >2-2.5cm in diameter do not pass through the pylorus, 28 we expect the expanded sponge (which has a diameter of 3 cm) to stay in the stomach after detachment and because endoscopy is widely available, retrievability should be easily arranged in case of this unlikely event.
In a recent perspective article, it was reported that the Cytosponge had been recalled due to 2 cases of detachment in the CASE1 study (Food and Drug Administration Recall Z-2123-2016). 29 We would like to emphasize that the previous article refers to an alternative prototype device developed by Covidien GI Solutions (now Medtronic), not the original prototype patented by the Medical Research Council of the United Kingdom, which was used in all the studies reported here. Food and Drug Administration and Conformité Previous interview-based, quality study on 33 participants with GERD showed that Cytosponge is acceptable for most participants, as well as being preferred to endoscopy. 27 In our study, most patients (79.3%) scored their experience as at least "neutral" (VAS !5) and the median VAS score was 6.0 (IQR, 5.0-8.0). This was significantly higher when compared with endoscopy without sedation (VAS 5.0; IQR, 3.0-7.0); however, lower than endoscopy with sedation (VAS 8.0; IQR, 5.0-9.0) (P < .001 for both comparisons). It must be stressed, that the Cytosponge has other advantages as a screening tool, when compared with the latter. Endoscopy with sedation is an invasive, time-consuming procedure (usually several hours including recovery time) that requires the patient to avoid work and operating machinery for the subsequent 24 hours. Cytosponge can be performed in 5-7 minutes, within a primary care office, and (usually) does not involve any restrictions for the remaining part of the day.
Our review shows that patients with previously diagnosed chronic esophageal conditions (BE and EoE) have a higher acceptability rating for Cytosponge as compared with patients with GERD (P < .001). Supposedly, these patients are more aware of the importance of undergoing regular monitoring and are more used to repeated endoscopic examinations, which might explain the higher degree of acceptability. Patients examined in the primary care setting (n ¼ 518), had markedly higher acceptance, as compared with patients examined in the secondary care (n ¼ 2154). The unequal size of the groups could be a confounding factor. Nevertheless, we postulate that the more patient-friendly environment and individual approach of a primary care setting benefits the overall acceptability of the test. These results are promising, as the Cytosponge was developed to be a minimally invasive test for use in a primary-care offices.
Before implementation in clinical practice, randomized trial data is required to fully evaluate the diagnostic yield of Cytosponge and further evaluate its safety, acceptability and health economic outcomes. This is currently underway in the BEST3 trial (ISRCTN68382401], a 10,000-patient cluster randomized controlled trial which is being conducted in multiple UK primary care surgeries (more information: https://www.best3trial.org/thebest3-trial; funded by Cancer Research UK).
The main strength of the study is the direct access to original dataset to minimize missing data and ensure high quality of the statistical analyses. The studies were undertaken in several countries, for different indications and in different health care settings. This study does have some limitations. There were comparatively fewer acceptability scores recorded for endoscopy than the Cytosponge. This was because patients enrolled onto the BEST1 trial did not have the acceptability score recorded following endoscopy. Furthermore, the VAS is a crude measure of acceptability and further quantitative and qualitative interviews will be required to fully understand the patient experience. Some of the studies included in this analysis had more complex tools to measure patients' experience, such as impact event score or Spielberger State-Trait Anxiety Inventory; however, we did not include them in this analysis because they were not used in all the studies.
Conclusions
In conclusion, in this first review of clinical data on safety and acceptability of Cytosponge we have demonstrated that this device has a favorable safety and acceptability profile. The relative ease of administration and the higher safety profile as compared with endoscopy makes it a promising tool to be used in the primary care setting as a screening and surveillance test for esophageal disorders such as BE or EoE. Results from the ongoing BEST3 randomized trial will be critical before implementing the Cytosponge test for widespread use. 
